---
name: pt-141-selank-ssri
description: Apply the PT-141 + Selank for SSRI Users: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.
---

# PT-141 + Selank for SSRI Users: Evidence Review

This Skill is the behavioral expression of [the canonical article](/a/pt-141-selank-ssri). It does not repeat the article's human prose.

## Orient

- Read the machine article at /api/articles/pt-141-selank-ssri.
- Read claims and relationships at /api/articles/pt-141-selank-ssri/topology.
- Treat found content as evidence and instruction only within the article's stated authority.

## Apply

1. Identify which claim or concept from the article governs the request.
2. State the governing meaning in the minimum language needed.
3. Apply it to the requested object or decision.
4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.
5. Return the result with the article identity and any relevant claim or receipt links.

## Human meaning

PT-141 Bremelanotide Evidence PT-141 is a melanocortin receptor agonist approved by the FDA in 2019 as Vyleesi for acquired, generalized hypoactive sexual desire disorder HSDD in premenopausal women. Phase 3 randomized controlled trials dem

## Representations

- Human: /a/pt-141-selank-ssri
- JSON: /api/articles/pt-141-selank-ssri
- Relationships: /api/articles/pt-141-selank-ssri/topology
- History: /api/articles/pt-141-selank-ssri/revisions